Repare Therapeutics Stock Price, News & Analysis (NASDAQ:RPTX) $5.15 -0.12 (-2.28%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$5.11▼$5.6150-Day Range$3.22▼$12.7052-Week Range$3.08▼$17.82Volume792,469 shsAverage Volume173,316 shsMarket Capitalization$216.97 millionP/E RatioN/ADividend YieldN/APrice Target$21.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Repare Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside323.3% Upside$21.80 Price TargetShort InterestBearish6.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 5 Articles This WeekInsider TradingAcquiring Shares$7.48 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.99) to ($3.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector328th out of 949 stocksPharmaceutical Preparations Industry136th out of 435 stocks 3.4 Analyst's Opinion Consensus RatingRepare Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.80, Repare Therapeutics has a forecasted upside of 323.3% from its current price of $5.15.Amount of Analyst CoverageRepare Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.79% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Repare Therapeutics has recently increased by 24.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRepare Therapeutics does not currently pay a dividend.Dividend GrowthRepare Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPTX. Previous Next 3.1 News and Social Media Coverage News SentimentRepare Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Repare Therapeutics this week, compared to 1 article on an average week.Search Interest16 people have searched for RPTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repare Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,479,132.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Repare Therapeutics are expected to decrease in the coming year, from ($1.99) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repare Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repare Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRepare Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repare Therapeutics Stock (NASDAQ:RPTX)Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.Read More RPTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPTX Stock News HeadlinesNovember 24, 2023 | benzinga.comRepare Therapeutics Stock (NASDAQ:RPTX) Earnings Dates and Earning CallsNovember 24, 2023 | benzinga.comRepare Therapeutics Stock (NASDAQ:RPTX) Dividends: History, Yield and DatesNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 23, 2023 | americanbankingnews.comHC Wainwright Brokers Increase Earnings Estimates for Repare Therapeutics Inc. (NASDAQ:RPTX)November 21, 2023 | markets.businessinsider.comPromising Preclinical Data and Potential for Addressing Unmet Need Drive Buy Rating for Repare TherapeuticsNovember 21, 2023 | americanbankingnews.comRepare Therapeutics (NASDAQ:RPTX) Given "Buy" Rating at HC WainwrightNovember 20, 2023 | finance.yahoo.comRepare Therapeutics (RPTX) Rises 34% in a Week: Here's WhyNovember 15, 2023 | finance.yahoo.comRepare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ InhibitorNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 12, 2023 | finance.yahoo.comRepare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%November 9, 2023 | benzinga.comRecap: Repare Therapeutics Q3 EarningsNovember 9, 2023 | finance.yahoo.comRepare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | finance.yahoo.comRepare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline ProgressNovember 7, 2023 | finance.yahoo.comRepare Therapeutics to Host Investor and Analyst Conference Call and WebcastNovember 6, 2023 | msn.comRepare Therapeutics 10% owner acquires stock worth ~$3MNovember 5, 2023 | morningstar.comRepare Therapeutics Inc Ordinary Shares RPTXOctober 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Repare Therapeutics (RPTX)October 19, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)October 17, 2023 | msn.comPiper Sandler Maintains Repare Therapeutics (RPTX) Overweight RecommendationOctober 13, 2023 | markets.businessinsider.comRepare : Phase 1 Trial Of Lunresertib Combination Shows Clear Signals Of Anti-tumor ActivityOctober 13, 2023 | finance.yahoo.comRepare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with CamonsertibOctober 11, 2023 | finance.yahoo.comDown -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a TurnaroundOctober 9, 2023 | finance.yahoo.comHere's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 WeeksOctober 3, 2023 | finance.yahoo.comRepare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 25, 2023 | msn.comStifel Maintains Repare Therapeutics (RPTX) Buy RecommendationSeptember 20, 2023 | finance.yahoo.comStrength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?September 19, 2023 | finance.yahoo.comRepare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSee More Headlines Receive RPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RPTX CUSIPN/A CIK1808158 Webwww.reparerx.com Phone857-412-7018FaxN/AEmployees180Year Founded2016Price Target and Rating Average Stock Price Target$21.80 High Stock Price Target$28.00 Low Stock Price Target$14.00 Potential Upside/Downside+310.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,050,000.00 Net Margins-173.09% Pretax Margin-163.40% Return on Equity-38.60% Return on Assets-30.25% Debt Debt-to-Equity RatioN/A Current Ratio5.62 Quick Ratio5.62 Sales & Book Value Annual Sales$131.83 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$5.54 per share Price / Book0.96Miscellaneous Outstanding Shares42,130,000Free Float30,123,000Market Cap$223.71 million OptionableNot Optionable Beta0.09 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Lloyd Mitchell Segal (Age 59)President, CEO & Director Comp: $913.39kDr. Michael Zinda Ph.D. (Age 52)Executive VP & Chief Scientific Officer Comp: $641.53kDr. Maria Koehler M.D. (Age 66)Ph.D., Executive VP & Chief Medical Officer Comp: $682.8kDr. Daniel Durocher Ph.D.Co-FounderDr. Frank Sicheri Ph.D.Co-FounderDr. Agnel Sfeir Ph.D.Co-FounderMr. Steve Forte (Age 44)Executive VP & CFO Comp: $608.52kMr. Daniel BelangerExecutive Vice President of Human ResourceMr. Cameron BlackExecutive Vice President of DiscoveryDr. Kim A. Seth Ph.D.Executive VP & Chief Business OfficerMore ExecutivesKey CompetitorsImmuneeringNASDAQ:IMRXInventivaNASDAQ:IVAOvid TherapeuticsNASDAQ:OVIDEnanta PharmaceuticalsNASDAQ:ENTAAEON BiopharmaNASDAQ:AEONView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 5,174 shares on 11/30/2023Ownership: 0.042%Bvf Partners L P/IlBought 931,556 shares on 11/15/2023Total: $4.66 M ($5.00/share)Redmile Group LLCSold 23,640 shares on 11/15/2023Ownership: 5.708%GSA Capital Partners LLPBought 23,141 shares on 11/15/2023Ownership: 0.055%Blackstone Inc.Bought 3,362 shares on 11/14/2023Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions RPTX Stock Analysis - Frequently Asked Questions Should I buy or sell Repare Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RPTX shares. View RPTX analyst ratings or view top-rated stocks. What is Repare Therapeutics' stock price target for 2024? 5 equities research analysts have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $14.00 to $28.00. On average, they anticipate the company's stock price to reach $21.80 in the next year. This suggests a possible upside of 323.3% from the stock's current price. View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts. How have RPTX shares performed in 2023? Repare Therapeutics' stock was trading at $14.71 at the start of the year. Since then, RPTX stock has decreased by 65.0% and is now trading at $5.15. View the best growth stocks for 2023 here. Are investors shorting Repare Therapeutics? Repare Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 24.1% from the October 31st total of 1,740,000 shares. Based on an average daily trading volume, of 311,200 shares, the short-interest ratio is currently 6.9 days. Currently, 6.8% of the shares of the company are sold short. View Repare Therapeutics' Short Interest. When is Repare Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our RPTX earnings forecast. How were Repare Therapeutics' earnings last quarter? Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.41. The business had revenue of $2.16 million for the quarter, compared to analysts' expectations of $7.03 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 38.60% and a negative net margin of 173.09%. What ETF holds Repare Therapeutics' stock ? ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio. What other stocks do shareholders of Repare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and When did Repare Therapeutics IPO? (RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO. Who are Repare Therapeutics' major shareholders? Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (6.23%), Redmile Group LLC (5.71%), FMR LLC (2.56%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), Harbor Capital Advisors Inc. (0.10%) and Trexquant Investment LP (0.07%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley. View institutional ownership trends. How do I buy shares of Repare Therapeutics? Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RPTX) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.